Diagnosis and management of heparin-induced thrombocytopenia

References

• Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br. J. Haematol. 121, 535–555 (2003).
   PubMed Web of Science ®Google Scholar
• Chong BH. Heparin-induced thrombocytopenia. J. Thromb. Haemost. 1, 1471–1478 (2003).
   PubMed Web of Science ®Google Scholar
• Alving BM. How I treat heparin-induced thrombocytopenia and thrombosis. Blood 101, 31–37 (2003).
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126, S311– S3337 (2004).
   Google Scholar
• Walenga JM, Frenkel EP, Bick RL. Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other adverse effects of heparin-type therapy. Hematol. Oncol. Clin. North Am. 17, 259–282 (2003).
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am. J. Med. 101, 502–507 (1996).
   PubMed Web of Science ®Google Scholar
• Kitchens CS. Thrombocytopenia due to acute venous thromboembolism and its role in expanding the differential diagnosis of heparin-induced thrombocytopenia. Am. J. Hematol. 76, 69–73 (2004).
   PubMed Web of Science ®Google Scholar
• Gruel Y, Pouplard C, Lasne D et al. The homozygous FcγRIIIa-158V genotype is a risk factor for heparin-induced thrombocytopenia in patients with antibodies to heparin-platelet factor 4 complexes. Blood 104, 2791–2793 (2004).
   PubMed Web of Science ®Google Scholar
• Walenga JM, Jeske WP, Prechel MM, Bakhos M. Newer insights on the mechanism of heparin-induced thrombocytopenia. Semin. Thromb. Hemost. 30(Suppl. 1), 57–67 (2004).
   PubMed Web of Science ®Google Scholar
• Eslin DE, Zhang C, Samuels KJ et al. Transgenic mice studies demonstrate a role for platelet factor 4 in thrombosis: dissociation between anticoagulant and antithrombotic effect of heparin. Blood 104(10), 3173–3180 (2004).
   PubMed Web of Science ®Google Scholar
• Pouplard C, Iochmann S, Renard B et al. Induction of monocyte tissue factor expression by antibodies to heparin–platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood 97, 3300–3302 (2001).
   PubMed Web of Science ®Google Scholar
• Ahmad S, Bacher HP, Lassen MR et al. Investigations of the immunoglobulin subtype transformation of antiheparin-platelet factor 4 antibodies during treatment with a low-molecular-weight heparin (clivarin) in orthopedic patients. Arch. Pathol. Lab. Med. 127, 584–588 (2003).
   PubMed Web of Science ®Google Scholar
• Pouplard C, May MA, Iochmann S et al. Antibodies to platelet factor 4–heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation 99, 2530–2536 (1999).
   PubMed Web of Science ®Google Scholar
• Aird WC. The hematologic system as a marker of organ dysfunction in sepsis. Mayo Clin. Proc. 78, 869–881 (2003).
   PubMed Web of Science ®Google Scholar
• Prechel M, Jeske WP, Walenga JM. Laboratory methods for heparin-induced thrombocytopenia. Methods Mol. Med. 93, 83–93 (2004).
   PubMedGoogle Scholar
• Francis JL, Palmer GJ 3rd, Moroose R, Drexler A. Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery. Ann. Thorac. Surg. 75, 17–22 (2003).
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch. Intern. Med. 163, 2518–2524 (2003).
   PubMed Web of Science ®Google Scholar
• Gruel Y, Pouplard C, Nguyen P et al. Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia. Br. J. Haematol. 121, 786–792 (2003).
   PubMed Web of Science ®Google Scholar
• Betrosian AP, Theodossiades G, Lambroulis G et al. Heparin-induced thrombocytopenia with pulmonary embolism and disseminated intravascular coagulation associated with low-molecular-weight heparin. Am. J. Med. Sci. 325, 45–47 (2003).
   PubMed Web of Science ®Google Scholar
• Parody R, Oliver A, Souto JC, Fontcuberta J. Fondaparinux (ARIXTRA) as an alternative antithrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins. Haematologica 88, ECR32 (2003).
   PubMedGoogle Scholar
• Warkentin TE, Levine MN, Hirsh J et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N. Engl. J. Med. 332, 1330–1335 (1995).
   PubMed Web of Science ®Google Scholar
• Trossaert M, Gaillard A, Commin PL et al. High incidence of antiheparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery. Br. J. Haematol. 101, 653–655 (1998).
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Sheppard JA, Horsewood P et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 96, 1703–1708 (2000).
   PubMed Web of Science ®Google Scholar
• Jackson MR, Gillespie DL, Chang AS et al. The incidence of heparin-induced antibodies in patients undergoing vascular surgery: a prospective study. J. Vasc. Surg. 28, 439–444 (1998).
   PubMed Web of Science ®Google Scholar
• Bauer TL, Arepally G, Konkle BA et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 95, 1242–1246 (1997).
   PubMed Web of Science ®Google Scholar
• Visentin GP, Malik M, Cyganiak KA, Aster RH. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin:platelet factor 4 complexes. J. Lab. Clin. Med. 128, 376–383 (1996).
   PubMed Web of Science ®Google Scholar
• Dai MS, Hsieh AT, Chao TY. Catastrophic heparin-induced thrombocytopenia/thrombosis syndrome related to the use of a Port-A-Cath in a breast cancer patient receiving chemotherapy. Support. Care Cancer 12(7), 537–539 (2004).
   PubMed Web of Science ®Google Scholar
• Heeger PS, Backstrom JT. Heparin flushes and thrombocytopenia. Ann. Intern. Med. 105, 143 (1986).
   PubMed Web of Science ®Google Scholar
• Laster J, Silver D. Heparin-coated catheters and heparin-induced thrombocytopenia. J. Vasc. Surg. 7, 667–672 (1988).
   PubMed Web of Science ®Google Scholar
• Girolami B, Prandoni P, Stefani PM et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 101, 2955–2959 (2003).
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N. Engl. J. Med. 344, 1286–1292 (2001).
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Hirte HW, Anderson DR et al. Transient global amnesia associated with acute heparin-induced thrombocytopenia. Am. J. Med. 97, 489–491 (1994).
   PubMed Web of Science ®Google Scholar
• Rice L, Attisha WK, Drexler A, Francis JL. Delayed-onset heparin-induced thrombocytopenia. Ann. Intern. Med. 136, 210–215 (2002).
   PubMed Web of Science ®Google Scholar
• Abhyankar V, Kouides PA, Phatak PD. Heparin-induced thrombocytopenia is a cause of thromboembolism following coronary bypass surgery. Blood (1995) (Abstract 1995).
   Google Scholar
• Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126, S311–S337 (2004).
   Google Scholar
• Hong AP, Cook DJ, Sigouin CS, Warkentin TE. Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood 101, 3049–3051 (2003).
   PubMed Web of Science ®Google Scholar
• Lee DH, Warkentin TE, Denomme GA, Lagrotteria DD, Kelton JG. Factor V Leiden and thrombotic complications in heparin-induced thrombocytopenia. Thromb. Haemost. 79, 50–53 (1998).
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Kelton JG. Heparin-induced skin necrosis. Am. J. Med. 95, 662–664 (1993).
   PubMed Web of Science ®Google Scholar
• Opatrny L, Warner MN. Risk of thrombosis in patients with malignancy and heparin-induced thrombocytopenia. Am. J. Hematol. 76, 240–244 (2004).
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Heddle NM. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr. Hematol. Rep. 2, 148–157 (2003).
   PubMedGoogle Scholar
• Pouplard C, Amiral J, Borg JY et al. Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. Am. J. Clin. Pathol. 111, 700–706 (1999).
   PubMed Web of Science ®Google Scholar
• Gobbi G, Mirandola P, Tazzari PL et al. New laboratory test in flow cytometry for the combined analysis of serologic and cellular parameters in the diagnosis of heparin-induced thrombocytopenia. Cytometry 58B, 32–38 (2004).
   Google Scholar
• Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb. Haemost. 69, 344–350 (1993).
   PubMed Web of Science ®Google Scholar
• Cines DB, Kaywin P, Bina M, Tomaski A, Schreiber AD. Heparin-associated thrombocytopenia. N. Engl. J Med. 303, 788–795 (1980).
   PubMed Web of Science ®Google Scholar
• Lee DH, Warkentin TE, Denomme GA, Hayward CP, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia: detection of platelet microparticles using flow cytometry. Br. J. Haematol. 95, 724–731 (1996).
   PubMed Web of Science ®Google Scholar
• Amiral J, Peynaud-Debayle E, Wolf M et al. Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or low-molecular-weight heparin. Am. J. Hematol. 52, 90–95 (1996).
   PubMed Web of Science ®Google Scholar
• Geerts WH, Pineo GF, Heit JA et al. Prevention of Venous Thromboembolism: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126, 338S–3400 (2004).
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Elavathil LJ, Hayward CP et al. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann. Intern. Med. 127, 804–812 (1997).
   PubMed Web of Science ®Google Scholar
• Srinivasan AF, Rice L, Bartholomew JR et al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch. Intern. Med. 164, 66–70 (2004).
   PubMed Web of Science ®Google Scholar
• Smythe MA, Warkentin TE, Stephens JL, Zakalik D, Mattson JC. Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia. Am. J. Hematol. 71, 50–52 (2002).
   PubMed Web of Science ®Google Scholar
• Jeske WP, Walenga JM. Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia. Methods Mol. Med. 93, 61–82 (2004).
   PubMedGoogle Scholar
• Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb. Haemost. 70, 554–561 (1993).
   PubMed Web of Science ®Google Scholar
• Poncet B, Mahul P, Beraud AM et al. Failure of Orgaran therapy in a patient with a previous heparin-induced thrombocytopenia syndrome. Br. J. Haematol. 90, 969–970 (1995).
   PubMed Web of Science ®Google Scholar
• Kodityal S, Manhas AH, Udden M, Rice L. Danaparoid for heparin-induced thrombocytopenia: an analysis of treatment failures. Eur. J. Haematol. 71, 109–113 (2003).
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Lewis BE, Wildermann NM et al. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J. Invasive. Cardiol. 15, 611–616 (2003).
   PubMedGoogle Scholar
• Gordon G, Rastegar H, Schumann R, Deiss-Shrem J, Denman W. Successful use of bivalirudin for cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. J. Cardiothorac. Vasc. Anesth. 17, 632–635 (2003).
   PubMed Web of Science ®Google Scholar
• Bott JN, Reddy K, Krick S. Bivalirudin use in off-pump myocardial revascularization in patients with heparin-induced thrombocytopenia. Ann. Thorac. Surg. 76, 273–275 (2003).
   PubMed Web of Science ®Google Scholar
• Davis Z, Anderson R, Short D, Garber D, Valgiusti A. Favorable outcome with bivalirudin anticoagulation during cardiopulmonary bypass. Ann. Thorac. Surg. 75, 264–265 (2003).
   PubMed Web of Science ®Google Scholar
• Bittl JA, Strony J, Brinker JA et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N. Engl. J. Med. 333, 764–769 (1995).
   PubMed Web of Science ®Google Scholar
• Francis JL, Drexler A, Gwyn G. Bivalirudin, a direct thrombin inhibitor, is a safe and effective treatment for heparin-induced thrombocytopenia. Blood 102, (2003) (Abstract 571).
   Google Scholar
• Berilgen JE, Nguyen PH, Baker KR, Rice L. Bivalirudin treatment of heparin-induced thrombocytopenia. Blood 102, (2003) (Abstract 1969).
   Google Scholar
• Chew DP, Bhatt DL, Kimball W et al. Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. Am. J. Cardiol. 92, 919–923 (2003).
   PubMed Web of Science ®Google Scholar
• Robson R, White H, Aylward P, Frampton C. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender. Clin. Pharmacol. Ther. 71, 433–439 (2002).
   PubMed Web of Science ®Google Scholar
• Robson R. The use of bivalirudin in patients with renal impairment. J. Invas. Cardiol. 12(Suppl. F), F33–F36 (2000).
   PubMedGoogle Scholar
• Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch. Intern. Med. 163, 1849–1856 (2003).
   PubMed Web of Science ®Google Scholar
• Lewis BE, Wallis DE, Berkowitz SD et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 103, 1838–1843 (2001).
   PubMed Web of Science ®Google Scholar
• Greinacher A, Janssens U, Berg G et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators. Circulation 100, 587–593 (1999).
   PubMed Web of Science ®Google Scholar
• Greinacher A, Volpel H, Janssens U et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 99, 73–80 (1999).
   PubMed Web of Science ®Google Scholar
• Potzsch B, Madlener K, Seelig C et al. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass-assessment of the whole-blood ecarin clotting time. Thromb. Haemost. 77, 920–925 (1997).
   PubMed Web of Science ®Google Scholar
• Hursting MJ, Zehnder JL, Joffrion JL et al. The International Normalized Ratio during concurrent warfarin and argatroban anticoagulation: differential contributions of each agent and effects of the choice of thromboplastin used. Clin. Chem. 45, 409–412 (1999).
   PubMed Web of Science ®Google Scholar
• Sheth SB, DiCicco RA, Hursting MJ, Montague T, Jorkasky DK. Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin. Thromb. Haemost. 85, 435–440 (2001).
   PubMed Web of Science ®Google Scholar
• Warkentin TE. Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban. Thromb. Res. 110, 73–82 (2003).
   PubMed Web of Science ®Google Scholar
• Vanholder RC, Camez AA, Veys NM et al. Recombinant hirudin: a specific thrombin inhibiting anticoagulant for hemodialysis. Kidney Int. 45, 1754–1759 (1994).
   PubMed Web of Science ®Google Scholar
• Fischer KG, van de LA, Bohler J. Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis. Kidney Int. Suppl. 72, S46–S50 (1999).
   Google Scholar
• Matsuo T, Yamada T, Yamanashi T, Ryo R. Anticoagulant therapy with MD805 of a hemodialysis patient with heparin-induced thrombocytopenia. Thromb Res. 58, 663–666 (1990).
   PubMed Web of Science ®Google Scholar
• Eichler P, Friesen HJ, Lubenow N, Jaeger B, Greinacher A. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood 96, 2373–2378 (2000).
   PubMed Web of Science ®Google Scholar
• Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation 108, 2062–2065 (2003).
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Cook RJ, Marder VJ, Kelton JG. Comparison of heparin-induced thrombocytopenia antibody (HIT-Ab) generation and in vitro cross-reactivity after elective hip or knee replacement surgery in patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 102, (2003) (Abstract 569).
   Google Scholar
• Savi P, Chong BH, Greinacher A et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies. A blinded comparative multicenter study with unfractionated heparin. Blood 105(1), 139–144 (2004).
   PubMed Web of Science ®Google Scholar
• Walenga JM, Jeske WP, Samama MM et al. Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent. Expert. Opin. Investig. Drugs 11(3), 397–407 (2002).
   PubMed Web of Science ®Google Scholar
• Kuo KHM, Kovacs MJ. Successful treatment of heparin induced thrombocytopenia (HIT) with Fondaparinux. Blood 102, (2003) (Abstract 1147).
   Google Scholar
• Tardy B, Tardy-Poncet B, Fournel P et al. Lower limb veins should be systematically explored in patients with isolated heparin-induced thrombocytopenia. Thromb. Haemost. 82, 1199–1200 (1999).
   PubMed Web of Science ®Google Scholar
• Zwicker J, Bauer KA, Huang W-Y, Shaz B, Uhl L. The incidence of thrombosis in hospitalized patients with heparin-induced thrombocytopenia as identified by ELISA seropositivity. Blood 102, (2003) (Abstract 1966).
   Google Scholar
• Antoniou T, Kapetanakis EI, Theodoraki K et al. Cardiac surgery in patients with heparin-induced thrombocytopenia using preoperatively determined dosages of iloprost. Heart Surg. Forum 5, 354–357 (2002).
   PubMed Web of Science ®Google Scholar
• Jackson MR, Danby CA, Alving BM. Heparinoid anticoagulation and topical fibrin sealant in heparin-induced thrombocytopenia. Ann. Thorac. Surg. 64, 1815–1817 (1997).
   PubMed Web of Science ®Google Scholar
• Greinacher A. Lepirudin: a bivalent direct thrombin inhibitor for anticoagulation therapy. Expert. Rev. Cardiovasc. Ther. 2(3), 339–357 (2004).
   Google Scholar
• Edwards JT, Hamby JK, Worrall NK. Successful use of Argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient. Ann. Thorac. Surg. 75, 1622–1624 (2003).
   PubMed Web of Science ®Google Scholar
• Lubenow N, Selleng S, Wollert HG et al. Heparin-induced thrombocytopenia and cardiopulmonary bypass: perioperative argatroban use. Ann. Thorac. Surg. 75, 577–579 (2003).
   PubMed Web of Science ®Google Scholar
• Potzsch B, Klovekorn WP, Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N. Engl. J. Med. 343, 515 (2000).
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann. Thorac. Surg. 76, 2121–2131 (2003).
   PubMed Web of Science ®Google Scholar
• Ageno W, Crotti S, Turpie AG. The safety of antithrombotic therapy during pregnancy. Expert. Opin. Drug Saf. 3(2), 113–118 (2004).
   PubMedGoogle Scholar
• Myers B, Westby J, Strong J. Prophylactic use of danaparoid in high-risk pregnancy with heparin-induced thrombocytopaenia-positive skin reaction. Blood Coagul. Fibrinolysis 14, 485–487 (2003).
   PubMed Web of Science ®Google Scholar
• Rice L. Heparin-induced thrombocytopenia: myths and misconceptions (that will cause trouble for you and your patient). Arch. Intern. Med. 164, 1961–1964 (2004).
   PubMedGoogle Scholar
• Rice L, Abrams CS, Anstrom KJ et al. Thrombocytopenia is common among patients treated with heparin and is rarely detected and evaluated with serologictesting and hematology consultation: preliminary findings from the CATCH registry. Blood (2003) (Abstract 1968).
   Google Scholar